Agents and methods to elicit anti-tumor immune response
The invention provides an isolated, purified population of human cells comprising CD8 + T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8 + T cells, (b) reducing Cbl-b activity in the CD8 + T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8 + T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.
1. A method for making CD8+ T cells which do not require co-stimulation in order to become activated and proliferate, the method comprising:
(a) providing, from peripheral blood of a subject, a cell population comprising CD8+ T cells,
(b) reducing Cbl-b activity in the CD8+ T-cells by introducing an siRNA which targets Cbl-b, thereby creating CD8+ T cells which do not require co-stimulation to become activated and proliferate.
2. The method of claim 1 , comprising a step of stimulating the CD8+ T cells to proliferate, wherein the step is performed after step (b).
3. The method of claim 1 , wherein the subject has one or more solid tumors.
4. The method of claim 3 , wherein at least one of the one or more solid tumors expresses MHC-I with an antigen that can be recognized by cytotoxic T lymphocytes (CTLs).
5. The method of claim 3 , wherein one or more of the solid tumors is a metastatic tumor.
6. The method of claim 1 , wherein the siRNA comprises SEQ ID NO: 1 (5′-CAGGAGTATGAGACAGAAG-3′).
7. A method for inducing an anti-tumor immune response in a subject in need thereof, the method comprising:
(a) providing, from peripheral blood of the subject, a cell population comprising CD8+ T cells,
(b) reducing Cbl-b activity in the CD8+ T-cells by introducing an siRNA which targets Cbl-b, and
(c) administering the population of cells comprising CD8+ T cells with reduced Cbl-b activity to the subject.
8. The method of claim 7 , comprising a step of stimulating the CD8+ T cells to proliferate, wherein the step is performed after step (b).
9. The method of claim 7 , wherein the subject has one or more solid tumors.
10. The method of claim 9 , wherein at least one of the one or more solid tumors expresses MHC-I with an antigen that can be recognized by CTLs.
11. The method of claim 9 , wherein one or more of the solid tumors is a metastatic tumor.
12. The method of claim 7 , wherein the siRNA comprises SEQ ID NO: 1 (5′-CAGGAGTATGAGACAGAAG-3′).
13. A method of adoptive tumor immunotherapy in a subject in need thereof, the method comprising:
(a) providing, from peripheral blood of the subject, a cell population comprising CD8+ T cells,
(b) reducing Cbl-b activity in the CD8+ T-cells by introducing an siRNA which targets Cbl-b, and
(c) administering the population of cells comprising CD8+ cells with reduced Cbl-b activity to the subject.
14. The method of claim 13 , comprising a step of stimulating the CD8+ T cells to proliferate, wherein the step is performed after step (b).
15. The method of claim 13 , wherein the subject has one or more solid tumors.
16. The method of claim 15 , wherein at least one of the one or more solid tumors expresses MHC-I with an antigen that can be recognized by CTLs.
17. The method of claim 15 , wherein one or more of the solid tumors is a metastatic tumor.
18. The method of claim 13 , wherein the siRNA comprises SEQ ID NO: 1 (5′-CAGGAGTATGAGACAGAAG-3′).
19. An isolated population of cells comprising CD8+ T cells with reduced Cbl-b activity compared to non-modified CD8+ T cells, wherein the isolated population of cells comprising CD8+ T cells have been isolated from peripheral blood of a subject who has one or more solid tumors, and wherein the Cbl-b activity has been reduced in the CD8+ T cells by introduction of an siRNA which targets Cbl-b.
20. The isolated population of cells of claim 19 , wherein the siRNA comprises SEQ ID NO: 1 (5′-CAGGAGTATGAGACAGAAG-3′).
21. The isolated population of cells of claim 19 , wherein the isolated population of cells comprising CD8+ T cells with reduced Cbl-b activity compared to non-modified CD8+ T cells is included in a pharmaceutical composition.
22. The isolated population of cells of claim 21 , wherein the pharmaceutical composition is used to treat cancer in the subject.
23. The isolated population of cells of claim 21 , wherein the pharmaceutical composition is used for immune rejection of a tumor in the subject.
24. The isolated population of cells of claim 19 , wherein at least one of the one or more solid tumors expresses MHC-I with an antigen that can be recognized by cytotoxic T lymphocytes (CTLs).
25. The isolated population of cells of claim 19 , wherein one or more of the solid tumors is a metastatic tumor.
26. A pharmaceutical composition comprising an isolated population of cells comprising CD8+ T cells with reduced Cbl-b activity, wherein the cells have been isolated from peripheral blood of a subject who has one or more solid tumors, and wherein the Cbl-b activity has been reduced in the CD8+ T cells by introduction of siRNA which targets Cbl-b, and wherein the Cbl-b activity is reduced compared to CD8+ T cells that have not had the siRNA introduced.
27. The pharmaceutical composition of claim 26 , wherein the siRNA comprises SEQ ID NO: 1 (5′-CAGGAGTATGAGACAGAAG-3′).
28. The pharmaceutical composition of claim 26 , wherein the pharmaceutical composition is used to treat cancer in the subject.
29. The pharmaceutical composition of claim 26 , wherein the pharmaceutical composition is used for immune rejection of a tumor in the subject.
30. The pharmaceutical composition of claim 26 , wherein at least one of the one or more solid tumors expresses MHC-I with an antigen that can be recognized by cytotoxic T lymphocytes (CTLs).
31. The pharmaceutical composition of claim 26 , wherein one or more of the solid tumors is a metastatic tumor.